Posted by Michael Wonder on 04 Jun 2024
CStone announces European Medicine Agency CHMP recommends approval of Cejemly (sugemalimab, anti-PD-L1) as first-line treatment for NSCLC
1 June 2024 - EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival and overall survival benefits of sugemalimab in combination with chemotherapy as a first-line treatment for non-small cell lung cancer.
CStone Pharmaceuticals today announced that the CHMP of the EMA has issued a positive opinion recommending approval of sugemalimab in combination with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer, which is one of the largest cancer indications and a leading cause of cancer death in the world.
